Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

BIA

- PMLiVE

Life sciences leaders warn against ‘unworkable’ changes to UK medicines scheme

The scheme could impact UK life sciences and NHS patient access to medicines

- PMLiVE

Health and Social Care Committee report on vaccination calls for urgent action in the UK

In England, coverage for childhood immunisations was below target in 2021 and 2022

- PMLiVE

UK life sciences sector sees substantial drop in international investment

The estimated value of inward foreign direct investment fell from £1.9bn in 2021 to £1bn in 2022

- PMLiVE

MHRA to introduce new UK clinical trials framework

The changes will aim to make it easier to gain approval and to run clinical trials in the UK

- PMLiVE

ABPI welcomes new NHS research guidance for integrated care systems

Included in the proposals are calls for a fixed rebate rate of 6.88% on all eligible NHS medicine sales to be paid by the industry

- PMLiVE

Novo Nordisk suspended from ABPI over ‘serious’ code of practice breaches

This is only the eighth time in the past 40 years that ABPI has issued such a significant sanction

- PMLiVE

Vertex moves ahead with its bid to develop a curative treatment for type 1 diabetes

Vertex has released results from its phase 1/2 trial for VX-880, a stem-cell-derived therapy that restores insulin production

- PMLiVE

Vertex expands further into cell and genetic therapies with a deal worth up to $1.2bn

A new deal will see Vertex harness Arbor Biotechnologies gene-editing technology to enhance its discovery efforts

- PMLiVE

Vertex to lead development of CRISPR Therapeutics-partnered gene therapy

Amended agreement sees Vertex take control of gene therapy programme

- PMLiVE

Vertex gains FDA fast track designation for diabetes stem cell therapy

Vertex says VX-880 has potential to restore pancreatic islet cell function, including insulin production, in type 1 diabetes patients

- PMLiVE

Moderna inks R&D agreements with Vertex and Chiesi

Biotech agrees to separate deals for the development of gene-editing and mRNA therapies

- PMLiVE

Vertex’s triple combination CF therapy to become available on the NHS

The drug will immediately become available to thousands of cystic fibrosis patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links